Szwarcberg Javier's most recent trade in Spruce Biosciences Inc was a trade of 4,690 Common Stock done at an average price of $4.5 . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 4.53 per share. | 31 Dec 2025 | 4,690 | 19,004 | - | 4.5 | 21,248 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 10,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 10,000 | 10,000 | - | - | Employee Stock Option (right to buy) | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 1,666 | 1,666 | - | - | Employee Stock Option (right to buy) | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Dec 2025 | 1,666 | 0 | - | - | Employee Stock Option (right to buy) | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,480 | 1,480 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,480 | 14,478 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,196 | 2,392 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2025 | 1,196 | 14,922 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.67 per share. | 11 Dec 2025 | 752 | 13,726 | - | 80.7 | 60,664 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.67 per share. | 11 Dec 2025 | 608 | 14,314 | - | 80.7 | 49,047 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2025 | 19,800 | 19,800 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 4,950 | 14,850 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 4,950 | 15,192 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.41 per share. | 10 Dec 2025 | 2,194 | 12,998 | - | 88.4 | 193,972 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 1,196 | 3,588 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2025 | 1,196 | 10,670 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.67 per share. | 10 Dec 2025 | 428 | 10,242 | - | 85.7 | 36,667 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2025 | 4,784 | 0 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Oct 2025 | 4,784 | 11,013 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2025 | 4,784 | 4,784 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 148.16 per share. | 20 Oct 2025 | 1,539 | 9,474 | - | 148.2 | 228,018 | Common Stock |
| Spruce Biosciences Inc | Szwarcberg Javier | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 358,800 | 358,800 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 358,800 | 466,121 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Szwarcberg Javier | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.54 per share. | 10 Dec 2024 | 128,020 | 338,101 | - | 0.5 | 68,747 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 111,000 | 506,796 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 111,000 | 222,000 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 89,700 | 427,801 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Szwarcberg Javier | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 89,700 | 269,100 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 10 Dec 2024 | 39,605 | 467,191 | - | 0.4 | 15,394 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.39 per share. | 10 Dec 2024 | 32,005 | 395,796 | - | 0.4 | 12,440 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 358,800 | 358,800 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 717,600 | 717,600 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 111,000 | 145,705 | - | 0 | Common Stock | |
| Spruce Biosciences Inc | Szwarcberg Javier | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 111,000 | 333,000 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Szwarcberg Javier | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 14 Dec 2023 | 38,384 | 107,321 | - | 1.7 | 63,717 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.98 per share. | 30 Jun 2023 | 20,000 | 34,705 | - | 1.0 | 19,550 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.93 per share. | 30 Dec 2022 | 14,705 | 14,705 | - | 0.9 | 13,717 | Common Stock |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2022 | 444,000 | 444,000 | - | - | Restricted Stock Units | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 750,000 | 750,000 | - | - | Employee Stock Option (right to buy) | |
| Spruce Biosciences Inc | Javier Szwarcberg | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 250,000 | 250,000 | - | - | Employee Stock Option (right to buy) |